Gene/SNP | Genotype | Non-CR | CR | Co-dominat P value | Dominant P value | Recessive P value |
---|---|---|---|---|---|---|
CYP2C19*2 | No. of patients with data | 90 | 149 | 0.020 | 0.031 | 0.000 |
 | *1/*1, n (%) | 52 (57.8) | 64 (43.0) | |||
 | *1/*2, n (%) | 37 (41.1) | 74 (49.7) | |||
 | *2/*2, n (%) | 1 (1.1) | 11 (7.4) | |||
CYP2C19*3 | No. of patients with data | 87 | 144 | 0.227 | N/A | 0.227 |
 | *1/*1, n (%) | 81 (93.1) | 127 (88.2) | |||
 | *1/*3, n (%) | 6 (6.9) | 17 (11.8) | |||
CYP2C19*2*3 | No. of patients with data | 87 | 144 | 0.072 | N/A | 0.072 |
 | *1/*1, n (%) | 46 (52.9) | 53 (36.8) | |||
 | *1/*2 + *1/*3, n (%) | 7 (8.0) | 2 (1.4) | |||
 | *2/*2 + *1/*3, n (%) | 0 (0.0) | 0 (0.0) | |||
P2RY12 rs2046934 | No. of patients with data | 87 | 141 | 0.945 | N/A | 0.945 |
 | GG, n (%) | 51 (58.6) | 82 (58.2) | |||
 | GA, n (%) | 36 (41.4) | 59 (41.8) | |||
P2RY12 rs6809699 | No. of patients with data | 86 | 141 | 0.043 | 0.115 | 0.021 |
 | CC, n (%) | 76 (88.4) | 107 (75.9) | |||
 | CA, n (%) | 10 (11.6) | 30 (21.3) | |||
 | AA, n (%) | 0 (0) | 4 (2.8) | |||
PIK3CA rs67562832 | No. of patients with data | 84 | 146 | 0.470 | 0.629 | 0.336 |
 | AA, n (%) | 64 (76.2) | 119 (81.5) | |||
 | AG, n (%) | 19 (22.6) | 24 (16.4) | |||
 | GG, n (%) | 1 (1.2) | 3 (2.1) | |||
PIK3CA rs77576241 | No. of patients with data | 86 | 146 | 0.303 | 0.442 | 0.133 |
 | CC, n (%) | 84 (97.7) | 136 (93.2) | |||
 | CT, n (%) | 2 (2.3) | 9 (6.2) | |||
 | TT, n (%) | 0 (0) | 1 (0.7) | |||
APBB1IP rs11015149 | No. of patients with data | 86 | 146 | 0.024 | 0.023 | 0.364 |
 | CC, n (%) | 73 (84.9) | 117 (80.1) | |||
 | CA, n (%) | 10 (11.6) | 29 (19.9) | |||
 | AA, n (%) | 3 (3.5) | 0 (0) | |||
TLN1 rs2295795 | No. of patients with data | 85 | 145 | 0.326 | 0.135 | 0.672 |
 | GG, n (%) | 47 (55.3) | 76 (52.4) | |||
 | GA, n (%) | 36 (42.4) | 59 (40.7) | |||
 | AA, n (%) | 2 (2.4) | 10 (6.9) | |||
TLN1 rs10814270 | No. of patients with data | 85 | 147 | 0.422 | 0.346 | 0.241 |
 | CC, n (%) | 21 (24.7) | 47 (32.0) | |||
 | CT, n (%) | 44 (51.8) | 73 (49.7) | |||
 | TT, n (%) | 20 (23.5) | 27 (18.4) | |||
ITGB3 rs3785873 | No. of patients with data | 85 | 145 | 0.236 | 0.634 | 0.090 |
 | GG, n (%) | 61 (71.8) | 88 (60.7) | |||
 | GA, n (%) | 20 (23.5) | 48 (33.1) | |||
 | AA, n (%) | 4 (4.7) | 9 (6.2) | |||
ITGB3 rs58847127 | No. of patients with data | 86 | 145 | 0.363 | 0.440 | 0.291 |
 | GG, n (%) | 71 (82.6) | 127 (87.6) | |||
 | GC, n (%) | 15 (17.4) | 17 (11.7) | |||
 | CC, n (%) | 0 (0) | 1 (0.4) | |||
ITGA2B rs3760364 | No. of patients with data | 86 | 144 | 0.853 | N/A | 0.853 |
 | TT (%) | 80 (93) | 133 (92.4) | |||
 | TA (%) | 6 (7) | 11 (7.6) | |||
RASGRP2 rs2230414 | No. of patients with data | 86 | 143 | 0.642 | 0.716 | 0.478 |
 | CC, n (%) | 39 (45.3) | 58 (40.6) | |||
 | CA, n (%) | 36 (41.9) | 69 (48.3) | |||
 | AA, n (%) | 11 (12.8) | 16 (11.2) |